EFN

Multiple Sclerosis (abbreviated as MS) is a chronic progressive disease of central nervous system where, myelin sheath – insulating covering of neuron is lost. It is believed to be auto immune dysfunction where immune system of the body attacks its own central nervous system. Often problems experienced are with respect to mobility and numbness, problems in speech and vision, weakness, loss of muscle coordination and bladder control. These patients are coupled with treatment and Physiotherapy.

Recent ground breaking trial report as published in Lancet, British Medical Journal that Fampridine has shown better results as compared to placebo in patients with MS. An extensive clinical trial was carried out in the late stage of Phase III, where 301 patients were involved between age 18 – 70 years for a period of over 14 weeks. Study drug – Fampridine was compared with placebo (similar looking medication with no active drug) in the trial and end points were tested in a timed 25-foot walk. Fampridine trial and drug was sponsored by Acorda Therapeutics.

Trial was divided into two controlled groups, one receiving study medication – Fampridine and other Placebo. Both the groups were given respective medication twice a day for 14 days. Patients were evaluated on the basis of walking speed after 2, 6, 10 and finally 14 weeks. Endpoint was to determine walking speed as the evaluation criteria for the study drug. Fampridine not only showed better results in walking speed but also showed significant increase in muscle strength.

In the last three out of four assessments, 35% of patients showed significant improvement in the controlled group of Fampridine as compared to only 8% of patients receiving placebo. Studies are still to be carried out for evaluating other effects of drug like visual function, strength and endurance. As mentioned by Andrew Goodman of the University of Rochester Medical Center that possible side-effects for the drug may include seizure and may increase in a dose dependent way. Before prescribing the medication, doctor has to evaluate the possible side effects of drugs after considering the condition of the patient.

MS is a frightening and lethal disease of central nervous system; it is believed that more that 2.5 million people have this disease. US Surveys report that 400,000 – 500,000 people in US are suffering from MS and out of which 64 – 85 % of them consider walking as the most challenging part. Occurrences of the disease have increased in modern times. In the available treatment options it is important to select the best suited for the disease stage and individual conditions. Any research that helps patient’s mobility and improve quality of life would be a great boon for the patients with Multiple Sclerosis.